Mesothelioma

• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DG … Ended
  2023-503996-38-00 1 2025-05-21 "Advanced or metastatic solid tumors"
• Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors Ended
  2022-502867-39-00 1 2023-09-29 "Advanced solid tumors including non-small cell lung cancer ("
• The effect of oral folinic acid to prevent pemetrexed induced adverse events. Ended
  2022-502345-10-00 6 2023-02-05 "Non small cell lung cancer (NSCLC), Mesothelioma, Thymoma"
• Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies Ended
  2023-508756-19-00 3 2019-10-29
• ROLLOVER STUDY FOR TAZEMETOSTAT Ended
  2023-510553-41-00 9 2016-08-29 "Subjects will receive tazemetostat as dictated in their ante"

Showing 1–5 of 5 trials